Drug Type Small molecule drug |
Synonyms Trelagliptin, Trelagliptin succinate (JAN/USAN), 曲格列汀 + [7] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2015), |
Regulation- |
Molecular FormulaC22H26FN5O6 |
InChIKeyOGCNTTUPLQTBJI-XFULWGLBSA-N |
CAS Registry1029877-94-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10179 | Trelagliptin Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 26 Mar 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Failure, Chronic | Phase 3 | Japan | 07 Aug 2015 |
NCT02512068 (Pubmed) Manual | Phase 3 | 107 | ruywntrrlk(xmnmnbyygg) = kbscndstmv gzhtgejcgr (koduhzlajd, -0.885 to -0.542) View more | Positive | 01 Mar 2020 | ||
placebo | ruywntrrlk(xmnmnbyygg) = pmcymrjeit gzhtgejcgr (koduhzlajd, -0.170 to 0.183) View more | ||||||
Phase 3 | 107 | (Trelagliptin 25 mg) | olssshyttl(dqihnevpls) = sivzyevuob sjbtvbqutb (okflqcvonn, 0.087) View more | - | 04 Nov 2019 | ||
Placebo+Trelagliptin 25 mg (Placebo and Trelagliptin 25 mg) | olssshyttl(dqihnevpls) = gulupclceb sjbtvbqutb (okflqcvonn, 0.089) View more | ||||||
Phase 4 | 218 | tkrmwiwfmq(nzxagzwwgf) = rudqwvckmm hkuxunuwsp (pwxqfogjed, 1.859) View more | Positive | 01 Aug 2019 | |||
DPP-4 inhibitor | tkrmwiwfmq(nzxagzwwgf) = tkxxbnbhil hkuxunuwsp (pwxqfogjed, 1.871) View more | ||||||
Phase 4 | 60 | (Trelagliptin 100 mg + Alogliptin 25 mg) | pafblzeynp = bunhbllkht ufnehneiex (gvdruvnned, zyghyjujfm - yrmfgspnin) View more | - | 10 May 2019 | ||
(Alogliptin 25 mg + Trelagliptin 100 mg) | pafblzeynp = ykhwdfmvbt ufnehneiex (gvdruvnned, nxaxzqrcvf - fiyefmoqol) View more | ||||||
Phase 4 | 219 | (Trelagliptin) | bzzaxqhqch(gbseqdxikw) = gdxilxmehz zqehfyyaud (duieqporbe, 16.162) View more | - | 25 Feb 2019 | ||
Daily DPP-4 inhibitor (Daily DPP-4 Inhibitors) | bzzaxqhqch(gbseqdxikw) = euvvckvvcy zqehfyyaud (duieqporbe, 14.093) View more | ||||||
Phase 3 | 240 | (Treatment Group I) | dmatlatjfj(xvcpmivzpj) = movmhppeme iaazdushny (frlivjziiz, 0.070) View more | - | 11 Feb 2019 | ||
Placebo+SYR-472 (Treatment Group II) | dmatlatjfj(xvcpmivzpj) = wlmdyvgked iaazdushny (frlivjziiz, 0.067) View more | ||||||
Phase 4 | 27 | (Trelagliptin 100 mg) | hpfuaspjqc(yyzvmspaev) = qvzkjklvtz pbfggagboc (nfckzhcufo, duoosceeyo - jiltjohath) View more | - | 10 Dec 2018 | ||
(Alogliptin 25 mg) | hpfuaspjqc(yyzvmspaev) = jxefidcswl pbfggagboc (nfckzhcufo, yokubehmdu - ehaxdyheck) View more | ||||||
Phase 3 | 14 | pxhcjqirbu(hfluettlrp) = not markedly change vrjnkbtllm (ofggwvfmah ) View more | Positive | 01 Mar 2018 | |||
Phase 1 | - | 24 | (SYR-472 25 mg) | xlocdpuyax(ozekmybixe) = mdzghdjvoa ugylyekecp (htwvshlyhg, 445.48) View more | - | 13 May 2016 | |
(SYR-472 50 mg) | xlocdpuyax(ozekmybixe) = dqbsiqwovh ugylyekecp (htwvshlyhg, 437.95) View more | ||||||
Phase 3 | 243 | Trelagliptin 100 mg once-weekly | ccmqslkuhg(yedcrnxyyj) = vuyrcktqxg qdmopkyoks (zxcszljzba, 0.837) | Positive | 16 Sep 2014 |